In both models, type of long-acting insulin analogue used was not significant, i.e. the daily doses of DET and GLAR did not differ significantly between T2D patients when administered once daily and when taking into account other factors that may influence insulin utilisation. The gene discussed is INS; the disease is type 2 diabetes mellitus.